- Clinical Study
- Risk Factors Associated with Disease Recurrence among Patients with Low-Risk Papillary Thyroid Cancer Treated at the University of the Philippines-Philippine General Hospital
-
Maria Cristina Magracia Jauculan, Myrna Buenaluz-Sedurante, Cecilia Alegado Jimeno
-
Endocrinol Metab. 2016;31(1):113-119. Published online March 16, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.1.113
-
-
4,452
View
-
49
Download
-
6
Web of Science
-
6
Crossref
-
Abstract
PDFPubReader
- Background
The management of papillary thyroid carcinoma (PTC) in high-risk patients is well-standardized. However, this is not the case for low-risk patients. Filipinos show a high incidence of recurrence of thyroid cancer. Thus, the identification of risk factors for recurrence in this population could potentially identify individuals for whom radioactive iodine (RAI) therapy might be beneficial. MethodsWe reviewed the medical records of adult Filipinos with low-risk PTC who underwent near-total or total thyroidectomy at the University of the Philippines-Philippine General Hospital. Multivariate logistic regression analysis was used to determine risk factors for recurrence. ResultsRecurrence was documented in 51/145 of patients (35.17%) included in this study. Possible risk factors such as age, sex, family history, smoking history, tumor size, multifocality, prophylactic lymph node dissection, initial thyroglobulin (Tg) level, initial anti-thyroglobulin (anti-Tg) antibody concentration, suppression of thyroid stimulating hormone production, and RAI therapy were analyzed. Multivariate analysis revealed that a tumor diameter 2 to 4 cm (odds ratio [OR], 9.17; 95% confidence interval [CI], 1.62 to 51.88; P=0.012), a tumor diameter >4 cm (OR, 16.46; 95% CI, 1.14 to 237.31; P=0.04), and a family history of PTC (OR, 67.27; 95% CI, 2.03 to 2228.96; P=0.018) were significant predictors of recurrence. In addition, RAI therapy (OR, 0.026; 95% CI, 0.01 to 0.023; P≤0.005), an initial Tg level ≤2 ng/mL (OR, 0.049; 95% CI, 0.01 to 0.23; P≤0.005), and an anti-Tg antibody level ≤50 U/mL (OR, 0.087; 95% CI, 0.011 to 0.67; P=0.019) were significant protective factors. ConclusionA tumor diameter ≥2 cm and a family history of PTC are significant predictors of recurrence. RAI therapy and low initial titers of Tg and anti-Tg antibody are significant protective factors against disease recurrence among low-risk PTC patients.
-
Citations
Citations to this article as recorded by
- Identifying and analyzing the key genes shared by papillary thyroid carcinoma and Hashimoto’s thyroiditis using bioinformatics methods
Ting-ting Liu, De-tao Yin, Nan Wang, Na Li, Gang Dong, Meng-fan Peng Frontiers in Endocrinology.2023;[Epub] CrossRef - Risk Stratification of Differentiated Thyroid Cancer at King Abdullah Specialized Children's Hospital Endocrinology Clinic in Riyadh, Saudi Arabia
Raed Al-Dahash, Abdullah Alsohaim, Ziyad N Almutairi , Khaled Z Almutairi , Abdulkarim Alharbi, Sulaiman Alayed, Abdullah Almuhanna, Rayan Alotaibi Cureus.2023;[Epub] CrossRef - Behaviour and epidemiology of differentiated thyroid cancer among filipinos in and outside the Philippines: Comparison between Qatar, Canada and Philippines
Mohamed Said Ghali, Walid El Ansari, Abdelrahman Abdelaal, Mohamed S. Al Hassan Annals of Medicine and Surgery.2022; 81: 104202. CrossRef - Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment‐Oriented Lymph Node Resection
Carlos Gustavo Rivera‐Robledo, David Velázquez‐Fernández, Juan Pablo Pantoja, Mauricio Sierra, Bernardo Pérez‐Enriquez, Raul Rivera‐Moscoso, Mónica Chapa, Miguel F. Herrera World Journal of Surgery.2019; 43(11): 2842. CrossRef - Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score–Matched Cohort Study
Suyeon Park, Won Gu Kim, Minkyu Han, Min Ji Jeon, Hyemi Kwon, Mijin Kim, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Suck Joon Hong, Young Kee Shong Thyroid.2017; 27(9): 1164. CrossRef - Articles inEndocrinology and Metabolismin 2016
Won-Young Lee Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
|